<DOC>
	<DOCNO>NCT00282425</DOCNO>
	<brief_summary>Scleroderma disease believe due immune cell , cell normally protect body causing damage body . There treatment effective treating disease . The likelihood progression disease severe disability death high . This study design examine whether treat patient high dose Cyclophosphamide Fludarabine ( drug reduce function immune system ) CAMPATH-1H ( protein kill immune cell think cause disease ) , follow return blood stem cell previously collect patient brother sister stop reverse disease . The purpose Cyclophosphamide , Fludarabine CAMPATH-1H decrease immune system . The purpose stem cell infusion restore blood production , severely impaired Cyclophosphamide , Fludarabine CAMPATH-1H , produce normal immune system longer attack body .</brief_summary>
	<brief_title>Allogeneic Hematopoietic Stem Cell Transplantation ( NST ) Patients With Systemic Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>Patient 1 . Age 18 55 year old 2 . An establish diagnosis scleroderma ( 84 ) 3 . Diffuse cutaneous scleroderma involvement proximal elbow knee Rodnan score ( see Appendix III ) &gt; 14 ( 85 ) And one following : 1 . DLCO &lt; 80 % predict decrease lung function ( TLC , DLCO FEV1 ) 10 % 12 month 2 . Active alveolitis bronchoalveolar lavage 3 . Pulmonary fibrosis alveolitis CT scan CXR 4 . Elevated ESR great equal 25mm/hour confirm second occasion least two week apart without evidence active infectious process . 5 . Abnormal EKG ( low QRS voltage , ventricular hypertrophy ) leave ventricle ( LV ) diastolic dysfunction ( express invert E/A ratio represent early late fill LV atrial contraction ) LV wall thickness 6 . Since pulmonary disease independent skin score ( NEJM , 2006 , 345:25 26552709 ) carry poor prognosis , patient may enrol lung involvement define active alveolitis BAL groundglass opacity CT , DLCO &lt; 80 % predict decrease lung function ( TLC ) , DLCO , FVC ) 10 % last 12 month . Patient 1 . Poor performance status ( ECOG &gt; =2 ) time entry , unless due disease . 2 . Significant end organ damage : 1 . LVEF &lt; 40 % deterioration LVEF exercise test MUGA echocardiogram 2 . Untreated lifethreatening arrhythmia 3 . Active ischemic heart disease heart failure 4 . DLCO le 45 % predict value , unless due disease . 5 . Pulmonary hypertension ( estimate systolic pulmonary arterial pressure &gt; 40 mmHg Doppler echocardiography measurement pulmonary arterial catheter ) 6 . Serum creatinine &gt; 2.0 mg/dl 7 . Liver cirrhosis , transaminases &gt; 3x normal limit bilirubin &gt; 2.0 unless due Gilberts disease 3 . HIV positive 4 . Uncontrolled diabetes mellitus illness opinion investigator would jeopardize ability patient tolerate aggressive treatment 5 . Prior history malignancy except localize basal cell squamous skin cancer . Other malignancy patient judge cured local surgical therapy , ( limit ) head neck cancer , stage I II breast cancer consider individual basis . 6 . Positive pregnancy test , inability unable pursue effective mean birth control , failure willingly accept comprehend irreversible sterility side effect therapy 7 . Psychiatric illness mental deficiency make compliance treatment inform consent impossible 8 . Inability give inform consent 9 . Age &lt; 18 &gt; 55 year old Donor 1 . Donor must HLA identical sibling HLA match cord blood donor 2 . If donor HLA match sibling , donor must &gt; 18 year age less 50 year old 3 . If multiple HLA match donor available , preference give sex , CMV status , case cord blood higher nucleated cell count 4 . If donor HLA match cord blood , cord blood stem cell obtain New York Blood Center Cord Blood Registry ( Tel 2125703230 ) internationally recognize registry , match available , Stemcyte ( 6268219860 ) commercial registry specialize minority donor . One unit HLA match cord blood unit infuse day zero Donor 1 . Age &gt; 50 year old &lt; 18 year old 2 . HIV positive 3 . Active ischemic heart disease heart failure 4 . Acute chronic active hepatitis 5 . Uncontrolled diabetes mellitus illness opinion investigator would jeopardize ability donor tolerate stem cell collection 6 . Prior history malignancy except localize basal cell squamous skin cancer . Other malignancy patient judge cured local surgical therapy , ( limit ) head neck cancer , stage I II breast cancer consider individual basis . 7 . Positive pregnancy test 8 . Psychiatric illness mental deficiency make compliance treatment inform consent impossible 9 . Major hematological abnormality platelet count less 100,000/ul , ANC less 1000/ul 10 . If donor sibling must collect minimum 2 . 106CD34+ cells/kg proceed transplant 11 . If donor cord blood unit ( ) minimum number nucleated cell available must 2 x 107 /kg . To achieve number nucleated cell , two unit HLA match cord blood may utilize . ( Wagner JE Blood . 2005 Feb 1 ; 105 ( 3 ) :13437 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>